VOLUME 2 (2011)
Table of Contents
|
| Wiring the oncogenic circuitry: Pin1 unleashes mutant p53 |
|
https://doi.org/10.18632/oncotarget.329
|
| 654-656 |
|
| Developing treatment strategies for rare cancers |
|
https://doi.org/10.18632/oncotarget.334
|
| 657 |
Research Papers
|
| Protection of acute myeloid leukaemia cells from apoptosis induced by frontline chemotherapeutics is mediated by haem oxygenase1 |
|
https://doi.org/10.18632/oncotarget.321
|
| 658-668 |
|
| Myc Enforces Overexpression of EZH2 in Early Prostatic Neoplasia via Transcriptional and Posttranscriptional Mechanisms |
|
https://doi.org/10.18632/oncotarget.327
|
| 669-683 |
Research Perspectives
|
| New Perspectives on the Role of Vitiligo in Immune Responses to Melanoma |
|
https://doi.org/10.18632/oncotarget.323
|
| 684-694 |
|
| NUAK2: an emerging acral melanoma oncogene |
|
https://doi.org/10.18632/oncotarget.325
|
| 695-704 |
|
| Human amniotic fluid stem cells as a model for functional studies of genes involved in human genetic diseases or oncogenesis |
|
https://doi.org/10.18632/oncotarget.328
|
| 705-712 |
|
| Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance persistence and longterm dormancy |
|
https://doi.org/10.18632/oncotarget.333
|
| 713-727 |
Methodological Reports
|
| Assessment of EGFR/HER2 dimerization by FRETFLIM utilizing Alexaconjugated secondary antibodies in relation to targeted therapies in cancers |
|
https://doi.org/10.18632/oncotarget.313
|
| 728-736 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC